| Literature DB >> 34838082 |
Sadhna Dhingra1, Firas Bahdi2, Sarah B May2, Mohamed O Othman3.
Abstract
BACKGROUND: Endoscopic submucosal dissection (ESD) is a novel endoscopic treatment for early esophageal adenocarcinoma (EAC). The western pathologists' experience with ESD specimens remains limited. This study aimed to correlate histopathologic features of Barrett's esophagus (BE)-associated adenocarcinoma in ESD resections with clinical outcomes to determine whether they aid future management decisions.Entities:
Keywords: Barrett’s esophagus; Endoscopic submucosal dissection; Mucosal adenocarcinoma; Submucosal adenocarcinoma; Tumor budding
Mesh:
Year: 2021 PMID: 34838082 PMCID: PMC8627628 DOI: 10.1186/s13000-021-01169-1
Source DB: PubMed Journal: Diagn Pathol ISSN: 1746-1596 Impact factor: 2.644
Fig. 1A. Endoscopic image of post esophageal endoscopic submucosal dissection. B. Gross image of the endoscopic submucosal dissection specimen
Fig. 2A. Invasive adenocarcinoma with tubuloinfiltrative pattern. Hematoxylin and Eosin stain. × 100. B. Invasive adenocarcinoma with tubulocystic pattern. Hematoxylin and Eosin stain. × 40
Fig. 3A. Invasive intramucosal adenocarcinoma infiltrating into the superficial layer of muscularis mucosae, Vieth and Stolte DOI: m2. B. Invasive intramucosal adenocarcinoma infiltrating into layer between superficial and deep muscularis mucosae, Vieth and Stolte DOI: m3. C. Invasive intramucosal adenocarcinoma infiltrating into the deep layer of muscularis mucosae, Vieth and Stolte DOI: m4. D. Invasive intramucosal adenocarcinoma infiltrating into the superficial submucosa ≤ 500 μm, Vieth and Stolte DOI: sm1. E. Invasive intramucosal adenocarcinoma infiltrating into submucosa to a depth between 500 to 1000 μm, Vieth and Stolte DOI: sm2. F. Invasive intramucosal adenocarcinoma infiltrating into deep submucosa > 1000 μm, Vieth and Stolte DOI: sm3. Hematoxylin and Eosin stain. × 40
Fig. 4A. Low tumor budding. B. Intermediate tumor budding. Hematoxylin and Eosin stain × 400. C. High tumor budding. Hematoxylin and Eosin stain × 200. D. Pankeratin immunostain with intermediate tumor budding, × 400. E. Pankeratin immunostain with high tumor budding, × 400
Fig. 5A. Tissue folding artefact due to improper processing and embedding. Hematoxylin and Eosin stain × 20. B. Pinhole artefact causing curling of tissue at edges leading to difficulty in peripheral margin interpretation. Hematoxylin and Eosin stain. × 40. C. Large pinhole artefact causing disruption of tissue at the edge. × 20
Specimen Processing Data
| Factor | Intramucosal Adenocarcinoma | Submucosal Adenocarcinoma | |
|---|---|---|---|
| < 5 cm | 18 (60%) | 10 (52.7%) | |
| 12 (40%) | 9 (47.4%) | ||
| En bloc | 27 (90%) | 18 (94.7%) | |
| 2 pieces | 1 (3.3%) | 1 (5.3%) | |
| 3 pieces | 2 (6.7%) | 0 (0%) | |
| 14 (46.7%) | 9 (47.4%) | ||
| Tumor nodule(s) | 20 (66.7%)* | 17 (89.5%)** | |
| Ulcerated mucosa | 3 (10%) | 0 (0%) | |
| No tumor | 7 (23.3%) | 2 (10.5%) | |
| Negative | 25 (83.3%) | 10 (52.6%) | |
| Positive | 3 (10%) | 2 (10.5%) | |
| Positive to negative | 1 (3.3%) | 0 (0%) | |
| Negative to positive | 1 (3.3%) | 7 (36.8%) | |
| Sm1 (< 500 μ) | 7 (23%) | 4 (21%) | |
| Sm2 ( | 21 (70%) | 12 (63%) | |
| Sm3 ( | 2 (7%) | 3 (16%) | |
| 2 (6.7%) | 6 (31.6%) | ||
| 3 (10%) | 2 (10.5%) | ||
Statistics presented as Frequency (%)
a Data are from 30 endoscopic submucosal dissection (ESD) resections in 24 patients, of which 26 were positive for intramucosal adenocarcinoma
b Data are from 19 ESD resections in 18 patients, of which 18 were positive for submucosal adenocarcinoma
*Multinodularity in 3 specimens
**Multinodularity in 5 specimens
Patients who underwent esophagectomy (n = 11)
| Adenocarcinoma Stage | Degree of tumor differentiation | Depth of invasion | LVI | Deep margin | Peripheral margin | Esophagectomy pathology AJCC/CAP staging |
|---|---|---|---|---|---|---|
| Intramucosal | Well | m3 | No | Negative | Positive | pT0N0 |
| Intramucosal | Poor | m3 | No | Negative | Negative | pT1aN0 |
| Intramucosal | Well | m3 | No | Positive | Negative | pT1aN0 |
| Submucosal | Poor | sm2 | Yes | Negative | Negative | pT1bN0 |
| Submucosal | Poor | sm1 | Yes | Negative | Negative | pT1aN1 |
| Submucosal | Moderate | >sm2 | No | Positive | Positive | pT1bN0 |
| Submucosal | Moderate | >sm1 | No | Positive | Positive | pT2N0 |
| Submucosal | Moderate | sm2 | No | Positive | Negative | pT0N0 |
| Submucosal | Well | sm1 | No | Negative | Positive | pT0N0 |
| Submucosal | Poor | sm2 | No | Positive* | Positive | pT1aN0 |
| Submucosal | Poor | sm1 | No | Negative | Positive | pT2N0 |
AJCC/CAP American Joint Commission on Cancer/College of American Pathologists; LVI lymphovascular invasion;
m3 involving the layer between the superficial and deep muscularis mucosae; sm1 submucosal invasion ≤500 μm, sm2 submucosal invasion > 500 μm,
* Single atypical gland in cauterized tissue at margin
Patients with positive deep margins (n = 10)
| Adenocarcinoma Stage | Tumor morphology | Deep margin | Follow-up | |
|---|---|---|---|---|
| Intramucosal | Low-risk features | Positive at site of tissue disruption with cautery effect | 6 month follow-up endoscopy and biopsies negative for carcinoma | |
| Intramucosal | Low-risk features | Positive at the site of tissue disruption with cautery artifact | 11 month follow-up with no recurrent carcinoma, just BE with low-grade dysplasia treated with RFA | |
| Intramucosal* | Low-risk features | Plane of resection “mucosal” at the site of positive deep margin | Esophagectomy showed residual tumor, pT1aN0 (AJCC/CAP staging, 8th edition) | |
| Submucosal | High-risk features | Tumor present at the edge of resection with both peripheral and deep margin positive | Esophagectomy showed residual tumor, pT1bN0 (AJCC/CAP staging, 8th edition) | |
| Submucosal | Low-risk features | Plane of resection “mucosal” at the site of positive deep margin | 3 and 9-month endoscopy with biopsy of ESD scar site showed BE but no dysplasia or carcinoma | |
| Submucosal | Low-risk features | Tumor present at the edge of resection | Esophagectomy showed residual tumor, pT2N0 (AJCC/CAP staging, 8th edition) | |
| Submucosal | High-risk features | Plane of resection “mucosal” at the site of positive deep margin | Esophagectomy showed no residual tumor, pT0N0 (AJCC/CAP staging, 8th edition) | |
| Submucosal** | High-risk features | Positive deep margin | Referred for more chemoradiation | |
| Submucosal** | High-risk features | Positive deep margin | Referred for more chemoradiation | |
| Submucosal | High-risk features | Single atypical gland in cauterized tissue at the deep margin | Esophagectomy showed residual tumor; pT1aN0 (AJCC/CAP staging, 8th edition) | |
AJCC/CAP American Joint Commission on Cancer/College of American Pathologists; BE Barrett’s esophagus; DOI depth of invasion; ESD endoscopic submucosal dissection; LVI lymphovascular invasion; RFA radiofrequency ablation
* Patient had esophageal stricture resistant to endoscopic intervention
**ESD was a debulking procedure post-chemoradiation in a patient with known esophageal adenocarcinoma
Tumor budding and outcomes (n = 8)
| Risk stratification based on morphology | Tumor budding score | Outcome |
|---|---|---|
Poorly differentiated Perineural invasion DOI: sm3 | 1 | Esophagectomy with residual tumor, pT1bN0 |
Poorly differentiated LVI present DOI: sm1 | 3 | Esophagectomy with residual tumor, pT1aN1 |
Poorly differentiated DOI: sm1 | 2 | Liver metastases |
DOI: sm2 R1 resection, deep and peripheral margin positive | 3 | Esophagectomy with residual tumor, pT1bN0 |
R1 resection, deep and peripheral margin positive | 3 | Esophagectomy with residual tumor, pT2N0 |
Poorly differentiated morphology Large-vessel invasion | 2 | Known case of esophageal adenocarcinoma, not surgical candidate, prior history of neoadjuvant chemotherapy, ESD performed for debulking |
Poorly differentiated adenocarcinoma LVI present | 2 | Known case of esophageal adenocarcinoma, not surgical candidate, prior history of neoadjuvant chemotherapy, ESD performed for debulking |
Poorly differentiated adenocarcinoma Deep margin negative Peripheral margin positive | 3 | Esophagectomy: residual adenocarcinoma pT2N0 |
DOI, depth of invasion; ESD endoscopic submucosal dissection; LVI lymphovascular invasion; p pathologic
Fig. 6Deep margin, positive for tumor due to superficial plane of resection. Hematoxylin and Eosin stain. × 40
Fig. 7A. Recommended thin paper pins for pinning the tissue on the board for proper fixation. B. Small pin hole and excellent orientation of the tissue edges for optimal assessment of peripheral margins. Hematoxylin and Eosin stain × 20
Histologic features of intramucosal and submucosal adenocarcinoma
| Feature | Intramucosal adenocarcinoma | Submucosal adenocarcinoma | |
|---|---|---|---|
| Histologic type | Tubuloinfiltrative | 13 (50%) | 8 (44.4%) |
| Tubulocystic | 9 (34.6%) | 4 (22.2%) | |
| Mixed | 3 (11.5%) | 1 (5.5%) | |
| Papillary | 1 (3.8%) | 2 (11.1%) | |
| Mixed tubular and Mucinous | 0 (0%) | 2 (11.1%) | |
| Mixed tubular and signet ring cell | 0 (0%) | 1 (5.5%) | |
| Pure mucinous | 0 (0%) | 0 (0%) | |
| Pure signet ring cell | 0 (0%) | 0 (0%) | |
| Tumor differentiation | Well differentiated | 18 (69.2%) | 4 (22.2%) |
| Moderately differentiated | 7 (26.9%) | 7 (38.9%) | |
| Poorly differentiated | 1 (3.8%) | 7 (38.9%) | |
| Lymphovascular invasion | 0 (0%) | 4 (22.2%) | |
| Large vessel invasion | 0 (0%) | 1 (5.5%) | |
| Perineural invasion | 0 (0%) | 1 (5.5%) | |
| Tumor budding | Low | 0 (0%) | 1 (5.5%) |
| Intermediate or high | 0 (0%) | 7 (38.9%) | |
| Peritumoral inflammatory response | Lymphoplasmacytic inflammation with lymphoid aggregates | 6 (23%) | 7 (38.9%) |
| Neutrophilic inflammation | 0 (0%) | 2 (11.1%) | |
| Desmoplasia | 0 (0%) | 8 (44.4%) | |
| Depth of invasion | m1 = 0 (0%) m2 = 7 (26.9%) m3 = 16 (61.5%) m4 = 3 (11.5%) | sm1 = 12 (66.7%) sm2 = 3 (16.7%) >sm2 = 3 (16.7%) | |
Statistics presented as Frequency (%)
a: Data are from 26 endoscopic submucosal dissection (ESD) resection specimens positive for intramucosal adenocarcinoma
b: Data are from 18 ESD resection specimens positive for submucosal adenocarcinoma
Patient follow up
| Adenocarcinoma (number of patients) | Resection risk profile | Follow up |
|---|---|---|
| Intramucosal adenocarcinoma, EAC T1a ( | ||
| R0 resection and low risk features ( | Endoscopic surveillance | |
| R0 resection and high risk features ( | Endoscopic surveillance for 27 months, developed recurrence and underwent esophagectomy | |
| R1 resection and low risk features ( | 2 patients followed by endoscopic surveillance | |
| 2 patients underwent esophagectomy | ||
| 2 patients underwent ESD ×2 | ||
| Submucosal adenocarcinoma EAC T1b ( | R0 resection and low risk features ( | Endoscopic surveillance |
| R0 resection and high risk features ( | 1 patient followed by endoscopic surveillance | |
| 2 patients underwent esophagectomy | ||
| 1 patient developed liver metastasis | ||
| R1 resection and low risk features ( | 4 patients followed by endoscopic surveillance | |
| 1 patient underwent esophagectomy | ||
| R1 resection and high risk features ( | 4 patients underwent esophagectomy | |
| 2 patients got chemoradiation (ESD was a debulking procedure) | ||
Pathologic variables associated with poor outcomes and better outcomes in ESD resections
| Poor outcomes* | Poor tumor differentiation |
| Submucosal depth of invasion | |
| Lymphovascular invasion | |
| Large vessel invasion | |
| Positive margins, specifically, positive deep margin | |
| Better outcomes* | Well to moderately differentiated tumor morphology |
| Submucosal depth of invasion < 500 μm (sm1) | |
| Negative margins, specifically, negative deep margin | |
| Absence of lymphovascular invasion |
* Our study also observed a trend in poor outcomes with tubulo-infiltrative morphology (versus tubulocystic morphology) and tumor budding. However, these could not be confirmed as independent risk factors because they were seen in association with other high risk histologic features